Nexalin Technology (NXL) Registration filing summary

Company overview and business model

• Designs and develops non-invasive neurostimulation devices for mental health conditions, focusing on anxiety, insomnia, depression, and other disorders.

• Devices use proprietary waveform technology, with Gen-2 and Gen-3 models emitting a 15 milliamp current for deeper brain stimulation.

• Revenue is currently derived from legacy device leases and consumables; new device sales in the U.S. are paused pending regulatory clearance.

• Pursuing a virtual clinic model for home-based treatment, integrating telehealth and app-based compliance monitoring.

• Joint venture in China enables clinical development and commercialization of Gen-2 devices, with regulatory approval for insomnia and depression.

Financial performance and metrics

• Incurred comprehensive losses of $4.7 million in 2023 and $1.0 million in Q1 2024; accumulated deficit of $78.1 million as of March 31, 2024.

• Cash and equivalents were $2.1 million as of March 31, 2024; pro forma $8.3 million post-offering.

• Revenue from China joint venture expected to begin in 2025; current revenues are limited.

Use of proceeds and capital allocation

• Estimated net proceeds of $6.16 million to be used for general corporate purposes, including working capital, operating expenses, and capital expenditures.

• Proceeds may also be allocated to strategic opportunities such as acquisitions or joint ventures as they arise.